世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000029980

医薬品受託研究機関(CRO)サービス市場-2026年までの世界予測

MarketsandMarkets

Contract Research Organization (CROs) Services Market- Global Forecast to 2026

発刊日 2021/07

言語英語

体裁PDF/389ページ

ライセンス/価格389ページ

0000029980

Single
5-user
Corporate
Global

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

医薬品受託研究機関(CRO)サービス市場:種類別(初期フェーズ、臨床、検査室)、治療領域別(オンコロジー、感染症)、分子タイプ別(ワクチン、CGT)、エンドユーザー別(製薬、バイオ医薬品、研究所)- 2026年までの世界予測

医薬品受託研究機関(CRO)サービス市場は2021年の532億ドルから、2026年までに865億ドルに達し、予測期間中のCAGRは10.7%と予想されます。医薬品受託研究機関(CRO)サービス市場の成長を促す主な要因としては、CROサービス市場を推進するための医薬品研究開発への投資の増加、臨床試験件数の増加、希少疾患の有病率の上昇などが挙げられます。

COVID-19が医薬品受託研究機関(CRO)サービス市場に与える影響

2019年12月に武漢(中国)で発生が始まる前はほとんど知られていなかったCOVID-19は地域的な危機から世界的な大流行へと移行しました。COVID-19のパンデミックは、世界中の医療システムへの負担を増大させています。WHOによると、COVID-19の確定症例は177,108,695例で、そのうち3,840,223人が死亡しました(2021年6月18日現在)。死亡者数が最も多かったのは北米で、ヨーロッパと東南アジアがそれに続いています。

世界保健機関(WHO)がCOVID-19のパンデミックの発生を公式に宣言したことによって、大手製薬会社とバイオ医薬品会社が一体となってSARS-CoV- 2ウイルスに対する検査キット、ワクチン、および薬剤を開発および販売するための研究開発と製造への取り組みが強化されました。多くの製薬およびバイオテクノロジー企業は、研究開発プロセスを促進するために世界中で長期業務提携、パートナーシップ、共同事業を通じてCROと協力関係を結びました。また、CROはCOVID-19研究専用のサービスを展開しました。2020年には、世界中でCOVID-19ワクチン、医薬品、診断薬の研究開発のための多くの新しいサービスの開始や業務提携、パートナーシップ、さまざまな製薬会社や学術機関との連携が実現しています。たとえば、2020年10月、Parexelのバイオテクノロジー部門はSynairgen plc(UK)と戦略的協力関係を結び、COVID-19で入院した患者を対象としたインターフェロンベータ(IFN-ベータ)治療のピボタル第III相試験を実施しました。

レポート詳細

目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 48)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CRO SERVICES MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 53)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2021-2026
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 64)
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021 VS. 2026 (USD MILLION)
FIGURE 14 CRO SERVICES MARKET, BY MOLECULE TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 CRO SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET

4 PREMIUM INSIGHTS (Page No. - 68)
4.1 CRO SERVICES MARKET OVERVIEW
FIGURE 17 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY PRODUCT & COUNTRY (2020)
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CRO SERVICES MARKET IN 2020
4.3 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 19 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2026
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2020
FIGURE 20 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2020
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CRO SERVICES MARKET FROM 2021 TO 2026

5 MARKET OVERVIEW (Page No. - 72)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing investment in pharmaceutical R&D
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2016
FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2021
5.2.1.2 Rising number of clinical trials creates significant demand for CRO services
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2021)
5.2.1.3 High cost of in-house drug development encourages pharma biotech companies to outsource contract R&D services
FIGURE 26 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
5.2.1.4 Rising prevalence of orphan and rare diseases creates new revenue pockets for CROs
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
FIGURE 27 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001-2020)
TABLE 2 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020
5.2.2.2 Rising demand for specialized testing services among end users
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals for clinical trials
5.2.3.2 Requirement for unique analytical testing approach for innovative formation
5.2.4 MARKET TRENDS
5.2.4.1 Revolutionary shift in CRO services market due to growing adoption of artificial intelligence-based tools for drug discovery
5.2.4.2 Increased outsourcing to emerging Asian economies
5.2.4.3 CRO industry consolidation
TABLE 3 LIST OF ACQUISITIONS
5.2.4.4 Integrated end-to-end R&D service solution
5.3 RANGES/SCENARIO
FIGURE 28 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CRO SERVICES MARKET
5.4 IMPACT OF COVID-19 OUTBREAK ON CRO SERVICES MARKET
FIGURE 29 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 30 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS
5.6 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020)
5.7 VALUE CHAIN ANALYSIS
FIGURE 31 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE
5.8 ECOSYSTEM ANALYSIS
FIGURE 32 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 TECHNOLOGY ANALYSIS
5.10 CASE STUDY
5.10.1 COVANCE FSPX DATA ANALYSIS USED TO DETERMINE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIAL
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR
5.11 REGULATORY ANALYSIS
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 DEGREE OF COMPETITION

6 CRO SERVICES MARKET, BY TYPE (Page No. - 98)
6.1 INTRODUCTION
TABLE 7 CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
6.2 CLINICAL RESEARCH SERVICES
6.2.1 GROWING NUMBER OF CLINICAL TRIALS AND PARTNERSHIPS WITH CROS PROPEL GROWTH OF SEGMENT
TABLE 8 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF JUNE 2021, BY LOCATION
TABLE 9 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
TABLE 10 CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 11 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 12 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 13 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 14 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.2 PHASE III CLINICAL RESEARCH SERVICES
6.2.2.1 Rising cost of Phase III trials and high number of patients recruited in these trials increases demand for cost effective CRO services
TABLE 15 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY
TABLE 16 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 17 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 18 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 19 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.3 PHASE II CLINICAL RESEARCH SERVICES
6.2.3.1 Long duration of Phase II studies provides growth opportunities for CROs
TABLE 20 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 21 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 22 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 23 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 24 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.4 PHASE I CLINICAL RESEARCH SERVICES
6.2.4.1 Robust pipeline of pharmaceutical companies drives segment growth
TABLE 25 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES
TABLE 26 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 27 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 28 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 29 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.2.5 PHASE IV CLINICAL RESEARCH SERVICES
6.2.5.1 Rising number of CROs providing post-marketing surveillance drives segment growth
TABLE 30 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 31 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 32 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 33 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 34 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3 EARLY-PHASE DEVELOPMENT SERVICES
6.3.1 RISING NEED FOR EARLY-PHASE DEVELOPMENT STUDIES FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
FIGURE 34 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2019)
TABLE 35 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
TABLE 36 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 37 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 38 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 39 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 40 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.2 CHEMISTRY, MANUFACTURING & CONTROL SERVICES
6.3.2.1 High demand for CMC services to check quality standards of drugs
TABLE 41 CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 42 NORTH AMERICA: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 43 EUROPE: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 44 ASIA PACIFIC: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.3 PRECLINICAL SERVICES
6.3.3.1 Rising demand for preclinical services for PK/PD and toxicology testing propels growth of segment
TABLE 45 PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 46 PRECLINICAL SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 47 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 48 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 49 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.4 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES
6.3.4.1 Increasing importance of studies to determine pharmacokinetic behavior of drug candidates to drive segment
TABLE 50 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 51 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 52 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 53 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.5 TOXICOLOGY TESTING SERVICES
TABLE 54 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 55 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 56 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 57 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.6 OTHER PRECLINICAL SERVICES
6.3.6.1 Increasing use of molecular imaging, flow cytometry, and immunohistochemistry to boost segment
TABLE 58 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 59 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 60 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 61 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.3.7 DISCOVERY STUDIES
6.3.7.1 Rising importance of CRO services for target identification and validation to promote segment growth
TABLE 62 DISCOVERY STUDIES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 63 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 64 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 65 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4 LABORATORY SERVICES
6.4.1 INCREASING IMPORTANCE OF LAB SERVICES TO ENSURE REGULATORY COMPLIANCE TO PROPEL SEGMENT GROWTH
TABLE 66 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 67 LAB SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 68 LAB SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 69 NORTH AMERICA: LAB SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 70 EUROPE: LAB SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 71 ASIA PACIFIC: LAB SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.2 ANALYTICAL TESTING SERVICES
6.4.2.1 Increasing demand for analytical testing for all stages of drug development drive growth of segment
TABLE 72 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 73 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 74 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 75 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 76 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.3 PHYSICAL CHARACTERIZATION
6.4.3.1 Increasing demand for physical characterization to reduce risk of product failure drives segment growth
TABLE 77 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 78 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 79 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 80 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.4 RAW MATERIAL TESTING
6.4.4.1 High demand for testing services to ensure quality and purity of raw materials drives growth of segment
TABLE 81 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 82 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 83 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 84 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.5 BATCH RELEASE TESTING
6.4.5.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel segment growth
TABLE 85 BATCH RELEASE TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 86 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 87 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 88 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.6 STABILITY TESTING
6.4.6.1 Used to ensure long-term quality, safety, and efficacy of pharmaceutical products
TABLE 89 STABILITY TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 90 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 91 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 92 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.7 OTHER ANALYTICAL TESTING
6.4.7.1 Demand for analytical method validation, cleaning validation, and microbial testing to propel segment growth
TABLE 93 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 94 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 95 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 96 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.4.8 BIOANALYTICAL TESTING SERVICES
6.4.8.1 High demand for bioanalytical testing due to growing use of macromolecules and biosimilars
TABLE 97 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 98 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 99 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.5 CONSULTING SERVICES
6.5.1 INCREASING ADOPTION OF CONSULTING SERVICES FOR QUALITY ASSURANCE PURPOSES PROPELS SEGMENT GROWTH
TABLE 101 CONSULTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 102 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 103 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 104 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
6.6 DATA MANAGEMENT SERVICES
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
TABLE 105 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 106 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 107 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 108 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 109 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 150)
7.1 INTRODUCTION
TABLE 110 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASING NUMBER OF CANCER CASES DRIVES GROWTH OF SEGMENT
FIGURE 35 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020)
FIGURE 36 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS)
TABLE 111 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 112 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 113 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 114 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 115 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
7.3 INFECTIOUS DISEASES
7.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES
TABLE 116 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD MILLION)
TABLE 117 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 118 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 119 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
7.4 NEUROLOGY
7.4.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS DRIVES MARKET
TABLE 120 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 121 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 122 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 123 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 124 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
7.5 CARDIOVASCULAR SYSTEM DISORDERS
7.5.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 125 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 126 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2019-2026 (USD MILLION)
TABLE 127 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 128 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 129 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
7.6 METABOLIC DISORDERS/ENDOCRINOLOGY
7.6.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE MARKET GROWTH
FIGURE 37 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
TABLE 130 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 131 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 132 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 133 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
7.7 IMMUNOLOGICAL DISORDERS
7.7.1 GROWING IMMUNOLOGIAL DRUGS PIPELINE RESULTING IN INCREASE IN OUTSOURCING ACTIVITIES
TABLE 134 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019-2026 (USD MILLION)
TABLE 135 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 136 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 137 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
7.8 RESPIRATORY DISORDERS
7.8.1 INCREASING PREVALENCE OF RESPIRATORY DISEASE TO SUPPORT GROWTH OF SEGMENT
TABLE 138 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020)
TABLE 139 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2019-2026 (USD MILLION)
TABLE 140 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 141 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 142 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
7.9 PSYCHIATRY
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH
TABLE 143 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2019-2026 (USD MILLION)
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 145 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019-2026 (USD MILLION)
7.10 DERMATOLOGY
7.10.1 INCREASING PREVALENCE OF SKIN DISORDERS PROPELS SEGMENT GROWTH
TABLE 147 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
TABLE 148 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 150 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
7.11 HEMATOLOGY
7.11.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 152 CRO SERVICES MARKET FOR HAEMATOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 153 NORTH AMERICA: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 154 EUROPE: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 155 ASIA PACIFIC: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
7.12 OPHTHALMOLOGY
7.12.1 GROWING NEED FOR OPTHALMOLOGY-RELATED CLINICAL TRIALS
TABLE 156 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2019-2026 (USD MILLION)
TABLE 157 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 158 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 159 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
7.13 GASTROINTESTINAL DISEASES
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES AND GROWING INVESTMENT IN R&D TO PROPEL MARKET
TABLE 160 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019-2026 (USD MILLION)
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 162 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
7.14 GENITOURINARY & WOMEN’S HEALTH
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES SEGMENT GROWTH
TABLE 164 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2019-2026 (USD MILLION)
TABLE 165 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 166 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 167 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD MILLION)
7.15 OTHER THERAPEUTIC AREAS
7.15.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPPORT SEGMENT GROWTH
TABLE 168 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019-2026 (USD MILLION)
TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)

8 CRO SERVICES MARKET, BY MOLECULE TYPE (Page No. - 185)
8.1 INTRODUCTION
TABLE 172 CRO SERVICES MARKET, BY MOLECULE TYPE, 2019-2026 (USD MILLION)
8.2 VACCINES
8.2.1 RISING FOCUS ON IMMUNIZATION FOR INFECTIOUS DISEASES FUELING MARKET GROWTH
TABLE 173 COVID-19 VACICNES IN PIPELINE
TABLE 174 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2019-2026 (USD MILLION)
8.3 CELL & GENE THERAPY
8.3.1 INCREASING FUNDING FOR R&D SUPPORTS MARKET GROWTH
8.4 OTHER MOLECULE TYPES

9 CRO SERVICES MARKET, BY END USER (Page No. - 190)
9.1 INTRODUCTION
TABLE 175 CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH
FIGURE 38 ANNUAL DRUG APPROVALS BY FDA’S CDER (2009-2018)
FIGURE 39 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011-2018
TABLE 176 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 178 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
9.3 MEDICAL DEVICE COMPANIES
9.3.1 INCREASE IN R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES FUELING MARKET GROWTH
FIGURE 40 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2010-2020)
FIGURE 41 R&D EXPENSES OF LEADING MEDICAL DEVICE COMPANIES (IN USD MILLION), 2020
TABLE 180 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019-2026 (USD MILLION)
TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 182 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
9.4 ACADEMIC INSTITUTES
9.4.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
TABLE 184 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2019-2026 (USD MILLION)
TABLE 185 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 186 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 187 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)

10 CRO SERVICES MARKET, BY REGION (Page No. - 202)
10.1 INTRODUCTION
TABLE 188 CRO SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 42 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
TABLE 189 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 190 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 191 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 192 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 193 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 194 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 195 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 196 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 197 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.2.1 US
10.2.1.1 Largest CRO services market in North America due to robust clinical trial activities
FIGURE 43 US CONTINUES TO DOMINATE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
TABLE 198 US: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 199 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 200 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 201 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 202 US: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 203 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 204 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 205 US: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing number of clinical trials to support market growth
TABLE 206 CANADA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 207 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 208 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 209 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 210 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 211 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 212 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 213 CANADA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3 EUROPE
FIGURE 44 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
TABLE 214 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 215 EUROPE: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 216 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 217 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 218 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 219 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 220 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 221 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 222 EUROPE: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Favorable location for clinical trials due to government support and flexible labor laws
TABLE 223 GERMANY: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 224 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 225 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 226 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 227 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 228 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 229 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 230 GERMANY: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth
FIGURE 45 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017 (USD MILLION)
TABLE 231 UK: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 232 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 233 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 234 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 235 UK: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 236 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 237 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 238 UK: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 High number of oncology clinical trials to drive market growth
TABLE 239 FRANCE: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 240 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 241 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 242 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 243 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 244 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 245 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 246 FRANCE: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Low drug approval time and growing number of clinical trials to drive market growth
TABLE 247 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 248 ITALY: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 249 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 250 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 251 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 252 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 253 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 254 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 255 ITALY: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Short study start-up times and rising R&D expenditure to boost market growth
FIGURE 46 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011-2017
TABLE 256 SPAIN: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 257 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 258 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 259 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 260 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 261 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 262 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 263 SPAIN: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 264 ROE: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 265 ROE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 266 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 267 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 268 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 269 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 270 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 271 ROE: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 47 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
TABLE 272 APAC: CRO SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 273 APAC: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 274 APAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 275 APAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 276 APAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 277 APAC: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 278 APAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 279 APAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 280 APAC: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Dominates market due to robust pharmaceutical industry and presence of prominent CROs
TABLE 281 CHINA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 282 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 283 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 284 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 285 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 286 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 287 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 288 CHINA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Strong focus on research to drive market growth
TABLE 289 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 290 JAPAN: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 291 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 292 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 293 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 294 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 295 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 296 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 297 JAPAN: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Growing pharmaceutical industry to drive market growth
TABLE 298 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 299 INDIA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 300 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 301 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 302 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 303 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 304 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 305 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 306 INDIA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Favorable location for drug discovery due to large number of research institutes
TABLE 307 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 308 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 309 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 310 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 311 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 312 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 313 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 314 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Government initiatives and growing R&D activities for drug development to drive market growth
TABLE 315 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 316 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 317 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 318 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 319 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 320 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 321 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 322 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 323 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 324 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 325 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 326 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 327 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 328 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 329 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 330 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 331 ROAPAC: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH
TABLE 332 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 333 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 334 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 335 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 336 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 337 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 338 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 339 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
TABLE 340 MEA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 341 MEA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
TABLE 342 MEA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 343 MEA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 344 MEA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 345 MEA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 346 MEA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
TABLE 347 MEA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 277)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 48 CRO SERVICES MARKET: STRATEGIES ADOPTED
11.3 REVENUE ANALYSIS
FIGURE 49 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS
11.4 MARKET SHARE ANALYSIS
FIGURE 50 CRO SERVICES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
11.5 COMPANY EVALUATION QUADRANT
FIGURE 51 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX, 2020
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
FIGURE 52 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2020
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
11.7 COMPETITIVE BENCHMARKING
11.7.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
FIGURE 53 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.7.2 COMPANY INDUSTRY FOOTPRINT (20 COMPANIES)
TABLE 348 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.7.3 COMPANY SERVICE OFFERING FOOTPRINT (20 COMPANIES)
TABLE 349 SERVICE OFFERING FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.7.4 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
TABLE 350 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
11.8 COMPETITIVE SCENARIO AND TRENDS
11.8.1 SERVICES LAUNCHES
TABLE 351 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2017-NOVEMBER 2020
11.8.2 DEALS
TABLE 352 CRO SERVICES MARKET: DEALS, JANUARY 2017-NOVEMBER 2020
11.8.3 OTHER DEVELOPMENTS
TABLE 353 CRO SERVICES MARKET: EXPANSION, JANUARY 2017-NOVEMBER 2020

12 COMPANY PROFILES (Page No. - 293)
12.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 IQVIA
TABLE 354 IQVIA: BUSINESS OVERVIEW
FIGURE 54 IQVIA: COMPANY SNAPSHOT
TABLE 355 IQVIA: SERVICE OFFERINGS
TABLE 356 IQVIA: SERVICE LAUNCHES
TABLE 357 IQVIA: DEALS
TABLE 358 IQVIA: EXPANSION
12.1.2 LABCORP
TABLE 359 LABCORP: BUSINESS OVERVIEW
FIGURE 55 LABCORP: COMPANY SNAPSHOT
TABLE 360 LABCORP: SERVICE OFFERINGS
TABLE 361 LABCORP: SERVICE LAUNCHES
TABLE 362 LABCORP: DEALS
TABLE 363 LABCORP: EXPANSION
12.1.3 SYNEOS HEALTH INC.
TABLE 364 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
FIGURE 56 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
TABLE 365 SYNEOS HEALTH INC.: SERVICE OFFERINGS
TABLE 366 SYNEOS HEALTH INC: SERVICE LAUNCHES
TABLE 367 SYNEOS HEALTH INC.: DEALS
12.1.4 WUXI APPTEC
TABLE 368 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 57 WUXI APPTEC: COMPANY SNAPSHOT
TABLE 369 WUXI APPTEC : SERVICE OFFERINGS
TABLE 370 WUXI APPTEC: SERVICE LAUNCHES
TABLE 371 WUXI APPTEC: DEALS
TABLE 372 WUXI APPTEC: EXPANSION
12.1.5 CHARLES RIVER LABORATORIES
TABLE 373 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 58 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 374 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
TABLE 375 CHARLES RIVER LABORATORIES: DEALS
TABLE 376 CHARLES RIVER LABORATORIES: EXPANSION
12.1.6 PAREXEL INTERNATIONAL
TABLE 377 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
TABLE 378 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
TABLE 379 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
TABLE 380 PAREXEL INTERNATIONAL: DEALS
TABLE 381 PAREXEL INTERNATIONAL: EXPANSION
12.1.7 PRA HEALTH SCIENCES
TABLE 382 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
FIGURE 59 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
TABLE 383 PRA HEALTH SCIENCES: SERVICE OFFERINGS
TABLE 384 PRA HEALTH SCIENCES: SERVICE LAUNCHES
TABLE 385 PRA HEALTH SCIENCES: DEALS
TABLE 386 PRA HEALTH SCIENCES: EXPANSION
12.1.8 PPD INC
TABLE 387 PPD INC: BUSINESS OVERVIEW
FIGURE 60 PPD INC: COMPANY SNAPSHOT
TABLE 388 PPD INC: SERVICE OFFERINGS
TABLE 389 PPD: SERVICE LAUNCHES
TABLE 390 PPD: DEALS
TABLE 391 PPD: EXPANSION
12.1.9 ICON PLC
TABLE 392 ICON PLC: BUSINESS OVERVIEW
FIGURE 61 ICON PLC: COMPANY SNAPSHOT
TABLE 393 ICON PLC: SERVICE OFFERINGS
TABLE 394 ICON PLC : SERVICE LAUNCHES
TABLE 395 ICON PLC: DEALS
12.1.10 MEDPACE HOLDINGS INC
TABLE 396 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
FIGURE 62 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
TABLE 397 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
TABLE 398 MEDPACE HOLDINGS INC: DEALS
TABLE 399 MEDPACE HOLDINGS INC: EXPANSION
12.1.11 SGS
TABLE 400 SGS: BUSINESS OVERVIEW
FIGURE 63 SGS: COMPANY SNAPSHOT
TABLE 401 SGS: SERVICE OFFERINGS
TABLE 402 SGS: DEALS
12.1.12 FRONTAGE HOLDINGS CORPORATION
TABLE 403 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 64 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 404 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
TABLE 405 FRONTAGE HOLDINGS CORPORATION: DEALS
TABLE 406 FRONTAGE HOLDINGS CORPORATION: EXPANSION
12.1.13 PSI CRO AG
TABLE 407 PSI CRO AG: BUSINESS OVERVIEW
TABLE 408 PSI CRO AG: SERVICE OFFERINGS
TABLE 409 PSI CRO AG: EXPANSION
12.1.14 BIO AGILE THERAPEUTICS
TABLE 410 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
TABLE 411 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
12.1.15 FIRMA CLINICAL RESEARCH
TABLE 412 FIRMA CLINICAL RESEARCH: BUSINESS OVERVIEW
TABLE 413 FIRMA CLINICAL RESEARCH: SERVICE OFFERINGS
12.1.16 ACCULAB LIFE SCIENCES
TABLE 414 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW
TABLE 415 ACCULAB LIFE SCIENCES: SERVICE OFFERINGS
12.1.17 NOVOTECH HEALTH HOLDINGS
TABLE 416 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW
TABLE 417 NOVOTECH HEALTH HOLDINGS: SERVICE OFFERINGS
TABLE 418 NOVOTECH HEALTH HOLDINGS: DEALS
12.1.18 GENETICIST INC.
TABLE 419 GENETICIST INC.: BUSINESS OVERVIEW
TABLE 420 GENETICIST INC.: SERVICE OFFERINGS
12.1.19 LINICAL AMERICAS
TABLE 421 LINICAL AMERICAS: BUSINESS OVERVIEW
TABLE 422 LINICAL AMERICAS: SERVICE OFFERINGS
TABLE 423 LINICAL AMERICAS: DEALS
12.1.20 CELERION
TABLE 424 CELERION.: BUSINESS OVERVIEW
TABLE 425 CELERION.: SERVICE OFFERINGS
TABLE 426 CELERION.: SERVICE LAUNCHES
12.2 OTHER PLAYERS
12.2.1 AZELIX
TABLE 427 AZELIX: COMPANY OVERVIEW
12.2.2 CTSERV
TABLE 428 CTSERV: COMPANY OVERVIEW
12.2.3 PEPGRA
TABLE 429 PEPGRA: COMPANY OVERVIEW
12.2.4 AXCENT ADVANCED ANALYTICS (A3)
TABLE 430 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
12.2.5 DOVE QUALITY SOLUTIONS
TABLE 431 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 381)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

この商品のレポートナンバー

0000029980

TOP